The Food and Drug Administration (FDA) Office of Women’s Health (OWH) has released a roadmap for research regarding women’s health, Deputy Director of Research Pamela Scott announced this week.
According to Scott, this roadmap would facilitate an improved process for regulators for products and technology that would benefit women’s health.
Under this road map, there are seven areas of focus. They include designing improvements for clinical studies and analysis; expanding post market data sources and analysis; facilitating enhanced health communication; and identifying gender and sexual differences with regard to emerging technologies. The purpose of such improvements is to facilitate advancements in biomarkers and the identification of viable modeling and simulation techniques.
Scott stated that the OWH has helped fund approximately 300 projects that have allowed researchers to better understand women’s health. She also noted that this roadmap would facilitate improvements in collaborative research in all important areas relating to the priorities of the FDA.
The OWH Research and Development Program was established in 1994. It has been tasked with the promotion of workshops, research and training, which allow the FDA to better serve women’s health needs.
Scott has been associated with the OWH’s efforts in research ever since her recovery from a broken ankle. She said that questions about how the devices that would be utilized in her own treatment worked with women’s health in mind prompted her decision to get involved.
